Skip to main content
SpringerLink
Log in

Should we take into account ESBLs in empirical antibiotic treatment?

  • What's New in Intensive Care
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

An Erratum to this article was published on 09 January 2017

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Abbreviations

BLBLI:

Beta-lactam/beta-lactam inhibitor combination

cUTI:

Complicated urinary tract infection

GNB:

Gram-negative bacteria

ICU:

Intensive care unit

ESBL:

Extended-spectrum β-lactamases

EARS:

European Antimicrobial Resistance Surveillance Network

References

  1. Gazin M, Paasch F, Goossens H, Malhotra-Kumar S, Mosar WP, Teams SWS (2012) Current trends in culture-based and molecular detection of extended-spectrum-beta-lactamase-harboring and carbapenem-resistant Enterobacteriaceae. J Clin Microbiol 50(4):1140–1146

    Article  PubMed  PubMed Central  Google Scholar 

  2. Razazi K, Derde LP, Verachten M, Legrand P, Lesprit P, Brun-Buisson C (2012) Clinical impact and risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria in the intensive care unit. Intensive Care Med 38(11):1769–1778

    Article  PubMed  Google Scholar 

  3. Jacoby GA, Munoz-Price LS (2005) The new beta-lactamases. N Engl J Med 352(4):380–391

    Article  CAS  PubMed  Google Scholar 

  4. Morrissey I, Hackel M, Badal R, Bouchillon S, Hawser S, Biedenbach D (2013) A review of 10 years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals 6(11):1335–1346

    Article  PubMed  PubMed Central  Google Scholar 

  5. European Centre for Disease Prevention and Control (2015) Antimicrobial resistance surveillance in Europe 2014. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-NET). ECDC, Stockholm

  6. Sader HS, Farrell DJ, Flamm RK, Jones RN (2014) Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009–2011). Diagn Microbiol Infect Dis 78(4):443–448

    Article  CAS  PubMed  Google Scholar 

  7. Tumbarello M, Spanu T, Sanguinetti M, Citton R, Montuori E, Leone F et al (2006) Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 50(2):498–504

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A et al (2012) Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55(7):943–950

    Article  CAS  Google Scholar 

  9. Poulakou G, Bassetti M, Timsit JF (2016) Critically ill migrants with infection: diagnostic considerations for intensive care physicians in Europe. Intensive Care Med 42(2):245–248

    Article  PubMed  Google Scholar 

  10. Rodriguez-Bano J, Cisneros JM, Cobos-Trigueros N, Fresco G, Navarro-San Francisco C, Gudiol C et al (2015) Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology. Enferm Infecc Y Microbiol Clin 33(5):337.e1–337.e21

    Article  Google Scholar 

  11. Harris AD, McGregor JC, Johnson JA, Strauss SM, Moore AC, Standiford HC et al (2007) Risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission. Emerg Infect Dis 13(8):1144–1149

    Article  PubMed  PubMed Central  Google Scholar 

  12. Barbier F, Pommier C, Essaied W, Garrouste-Orgeas M, Schwebel C, Ruckly S et al (2016) Colonization and infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure? J Antimicrob Chemother 71(4):1088–1097

    Article  CAS  PubMed  Google Scholar 

  13. Goodman KE, Lessler J, Cosgrove SE, Harris AD, Lautenbach E, Han JH et al (2016) A clinical decision tree to predict whether a bacteremic patient is infected with an extended-spectrum beta-lactamase-producing organism. Clin Infect Dis Off Publ Infect Dis Soc Am 63(7):896–903

    Article  PubMed  Google Scholar 

  14. Gutierrez-Gutierrez B, Bonomo RA, Carmeli Y, Paterson DL, Almirante B, Martinez-Martinez L et al (2016) Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. J Antimicrob Chemother 71(6):1672–1680

    Article  CAS  PubMed  Google Scholar 

  15. Burkhardt O, Kumar V, Katterwe D, Majcher-Peszynska J, Drewelow B, Derendorf H et al (2007) Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother 59(2):277–284

    Article  CAS  PubMed  Google Scholar 

  16. Gutierrez-Gutierrez B, Perez-Galera S, Salamanca E, de Cueto M, Calbo E, Almirante B et al (2016) A multinational, preregistered cohort study of beta-lactam/beta-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 60(7):4159–4169

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

JRB receives funding for research from the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III—co-financed by the European Regional Development Fund (ERDF) “A way to achieve Europe”, and the Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015).

Author information

Authors and Affiliations

  1. Infectious Diseases Division, Santa Maria Misericordia University Hospital, Udine, Italy

    Bassetti Matteo

  2. Unidad Clínica Intercentros de Enfermedades Infecciosas, Microbiología Y Medicina Preventiva, Hospitales Universitarios Virgen Macarena Y Virgen Del Rocío–IbiS and Departamento de Medicina, Universidad de Sevilla, Seville, Spain

    Jesús Rodríguez Baño

  3. Clinica Malattie Infettive, Azienda Ospedaliero-Universitaria “Santa Maria Della Misericordia”, Piazzale S. Maria Della Misericordian. 15, 33100, Udine, Italy

    Bassetti Matteo

Authors
  1. Bassetti Matteo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jesús Rodríguez Baño
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bassetti Matteo.

Ethics declarations

Conflicts of interest

MB serves on scientific advisory boards for AstraZeneca, Bayer, Cubist, Pfizer Inc, MSD, Tetraphase and Astellas Pharma Inc.; has received funding for travel or speaker honoraria from Algorithm, Angelini, Astellas Pharma Inc., AstraZeneca, Cubist, Pfizer MSD, Gilead Sciences, Novartis, Ranbaxy, Teva. JRB served on scientific advisory boards for AstraZeneca, Merck, InfectoPharm and Basilea, and has received honoraria as a speaker for AstraZeneca and Merck.

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/s00134-016-4652-5.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Matteo, B., Baño, J.R. Should we take into account ESBLs in empirical antibiotic treatment?. Intensive Care Med 42, 2059–2062 (2016). https://doi.org/10.1007/s00134-016-4599-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-016-4599-6

Keywords

Search

Navigation